Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
4/14/25 Bristol (BMY) Camzyos for Cardiomyopathy - Hypertrophic Subscribers Only Subscribers Only Subscribers Only
4/1/25 Cerevance CVN424 for Parkinson's Disease (PD) Subscribers Only Subscribers Only Subscribers Only
4/1/25 Compass Therapeutics (CMPX) Tovecimig for Biliary Tract Cancer Subscribers Only Subscribers Only Subscribers Only
3/31/25 Eli Lilly (LLY) LY3561774 for Dyslipidemia / Hypercholesterolemia Subscribers Only Subscribers Only Subscribers Only
3/31/25 AstraZeneca (AZN) AZD0780 for Dyslipidemia / Hypercholesterolemia Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
04/01/2025 Subscribers Only Subscribers Only Company - Divestment/Spinoff
04/12/2025 Subscribers Only Subscribers Only Trial Data - Updated Results
04/13/2025 Subscribers Only Subscribers Only Trial Data - Updated Results
04/15/2025 Subscribers Only Subscribers Only Progress Update - Product Launch (U.S.)
04/15/2025 Subscribers Only Subscribers Only Trial Data - Updated Results